Board of Directors: Leadership & experience | NeuroPointDX
 /  Board of Directors

NeuroPointDX is a division of Stemina Biomarker Discovery. Each of the members of our Board of Directors provides strong leadership and experience to both divisions of our business.

  • Kevin Krenitsky, MD
    President - OpGen

    Through December 2014, Dr. Krenitsky was chief commercial officer & SVP of International Strategy and previously chief operating officer of Foundation Medicine. He joined Foundation in June 2011 and was instrumental in taking the company from a start-up organization to a successful IPO in 2013, followed by a major 1.2B investment by Roche making them majority stakeholders. Prior to Foundation Medicine, he served as president of Enzo Clinical Labs, where he instituted a comprehensive strategic and operational plan that led to the introduction and launch of numerous FDA-approved esoteric tests, as well as several new laboratory developed tests. Dr. Krenitsky served as chief executive officer at both BioServe Biotechnologies, a global biotechnology company specializing in processing genetic diagnostic tests, and Parkway Clinical Laboratories, a clinical diagnostic lab providing comprehensive routine and esoteric testing. He also held various senior-level positions within Genomics Collaborative, Inc. (a SeraCare Life Sciences Company), a full-scale clinical and genomics research company. Dr. Krenitsky received a B.S. in business management from the University of Scranton and an M.D. from Jefferson Medical College (now the Sidney Kimmel Medical College) in Philadelphia. He is a former member of the Board of Directors of the New York State Clinical Lab Association and of BioServe Biotechnologies, and serves on the Board of Directors of Lumicell.


  • Andrew Ferrara
    CEO & Chairman - Boston HealthCare

    Mr. Ferrara’s line management experience included the management of pharmaceutical operations, including all aspects of marketing and sales, for both Lilly and Dista in France and a member of the Board of Lilly Industries in the United Kingdom. In May, 1984, he co-found Polygen Corporation, a computer software company serving the chemical and pharmaceutical research industries, and initiated a number of research and licensing agreements with academic institutions and major health care corporations in the United States, Europe and Japan. Since founding Boston Healthcare in 1993, Mr. Ferrara has been involved in the development of a number of companies. Presently he serves as the Chair of the Board at Inform Genomics and serves on the board of The University of the Sciences in Philadelphia. In addition, he is a Member of the Corporation of the Woods Hole Oceanographic Institution. Mr. Ferrara has been a guest speaker at numerous professional meetings and conferences.


  • R. Andrew Morgan, R.Ph
    Executive Vice President Regulatory Affairs & Quality Operations - Zurex Pharma and Zurex PharmAgra

    Before joining Genzyme, Andrew served as the Vice President of Regulatory, Quality, and Pharmaceutical Sciences at Bone Care International in Middleton and held that position until the company’s acquisition by Genzyme in July 2005. Prior to joining Bone Care, he was the Director of Regulatory Affairs for Celltech Pharmaceuticals, Inc. in Rochester, New York; and before joining Celltech he was the manager of regulatory affairs, labeling, and advertising compliance for Medeva Pharmaceuticals in Fort Worth Texas. He has over 25 years of experience in the industry helping lead small pharmaceutical companies’ growth while being responsible for and having expertise in regulatory affairs, quality control, quality assurance, drug development, manufacturing, labeling and advertising, and product compliance activities. Andrew currently serves on the WARF Accelerator Program as a Pharmaceutical Catalyst and on the Technology Advisory Board for the DaneVest Tech Fund. Mr. Morgan received his Bachelor of Science of Pharmacy degree from SWOSU School of Pharmacy in Weatherford, Oklahoma and is a registered pharmacist.


  • Elizabeth LR Donley, JD MBA MS
    Chief Executive Officer

    Ms. Donley brings a unique combination of business and legal experience to Stemina. She has more than twenty years of experience in intellectual property, law, and business management. Ms. Donley served as General Counsel and Director of Business Development for the Wisconsin Alumni Research Foundation (WARF) for more than eight years.

    During those eight years, Ms. Donley negotiated hundreds of licenses and sponsored research and collaboration agreements between industry and WARF, the intellectual property management organization for the University of Wisconsin. Ms. Donley also served as Managing Director of both WARF subsidiaries: WiSys Technology Foundation (WiSys) and WiCell Research Institute (WiCell).

    WiCell distributes human embryonic stem (hES) cells, trains researchers worldwide and conducts important research involving many aspects of hES cell research. In 2005, WiCell was awarded a $16 million contract by the National Institute of Health to serve as the National Stem Cell Bank.

    Prior to joining WARF in 1998, Ms. Donley practiced law with the law firm of Quarles & Brady in the areas of intellectual property law, business transactions, securities, and corporate law.


  • Scott Carr
    CEO - Modria

    Prior to Modria, Scott was CEO of YottaMark, where he led the launch and scaling of HarvestMark, the leading traceability and supply chain analytics platform for fresh food. As Executive Vice President at Digimarc Corporation, he was responsible for launching the company’s copyright protection business, leading the global program to deter PC-based counterfeiting of currency, and driving sales of the company’s secure identification solutions. Scott is the co-inventor of more than 50 patents. He holds a Bachelor of Science degree in Computer Science from Oregon State University and an executive MBA from the Stanford/AeA program.


  • Marc Schneebaum
    SVP & Chief Financial Officer, Madrigal Pharmaceuticals

    From 1997 to 2010, Mr. Schneebaum served as President, Chief Executive Officer, and a director of Sensors for Medicine and Science, Inc., an emerging medical technology company. From 1991 to 1997, he served as Senior Vice President, Finance, Business Development and Administration, and Chief Financial Officer of Genetic Therapy, Inc., a biotechnology company (acquired by Sandoz/Novartis). From 1987 to 1991, Mr. Schneebaum was a Vice President at Alex Brown & Sons Incorporated, a leading investment banking firm (now part of Deutsche Bank), where he participated in a variety of finance and strategic assignments. Mr. Schneebaum began his career in the accounting and auditing group at KPMG LLP, advancing to Senior Manager in the management consulting group. Mr. Schneebaum has served as a director of GenVec, Inc., a publicly traded biopharmaceutical company, since 2007. Mr. Schneebaum received his degree in Business Administration from the University of Maryland and is a Certified Public Accountant (inactive).


(608) 204-0104

504 S. Rosa Rd. Suite 150
Madison, WI 53719

contact@NeuroPointDx.com